Corcept Therapeutics (NASDAQ:CORT) shares plunged Wednesday after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for relacorilant, a treatment for hypertension caused by excessive cortisol levels.
Beijing has demanded an immediate halt to US arms sales to Taiwan, warning the moves are driving the Taiwan Strait closer to conflict.
China Natural Resources (NASDAQ:CHNR) saw its net loss widen in the first half of 2025, even as the company aggressively cut overhead and continued exploration at its lead-silver mine in Inner Mongolia.
Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.
Axsome Therapeutics (NASDAQ:AXSM) is poised to file for U.S. regulatory approval of its narcolepsy treatment, AXS-12, following a successful pre-New Drug Application (NDA) meeting with the Food and Drug Administration.
Cable One (NYSE:CABO) has named James Holanda as its next Chief Executive Officer, ending a high-stakes search for a leader to navigate the provider through a period of intensifying competition and shifting subscriber habits.
Smart Share Global (NASDAQ:EM), the Chinese mobile charging giant known as Energy Monster, is poised to go private after shareholders overwhelmingly approved a $327 million merger agreement at an extraordinary general meeting on Wednesday.
MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), completed its acquisition of PineBridge Investments on Tuesday, creating a combined investment powerhouse with approximately $734.7 billion in assets under management.
AtaiBeckley (NASDAQ:ATAI) has officially completed its redomiciliation from the Netherlands to Delaware, finalizing a corporate overhaul that follows the recent strategic combination of atai Life Sciences and Beckley Psytech.
Anghami (NASDAQ:ANGH) saw its revenue skyrocket in the first half of 2025, as the integration of the OSN+ video service transformed the Abu Dhabi-based company into a regional entertainment powerhouse.
Vanda Pharmaceuticals (NASDAQ:VNDA) has secured U.S. Food and Drug Administration approval for NEREUS™ (tradipitant), ending a four-decade drought in new pharmacological treatments for motion sickness.
Oriental Rise Holdings (NASDAQ:ORIS) has entered into a non-binding letter of intent to acquire a controlling interest in Hubei Daguan Tea Industry Group Co., a vertically integrated producer based in the tea-rich region of Yingshan County.
